Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

Blood (2003) 101 (3): 1071–1079.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals